Vedan­ta opens man­u­fac­tur­ing fa­cil­i­ty to pro­duce lead can­di­date as it heads for PhI­II

The mi­cro­bio­me start­up Vedan­ta, while still forg­ing ahead with the Phase III process for its Clostrid­ioides dif­fi­cile in­fec­tion can­di­date, has com­plet­ed a man­u­fac­tur­ing fa­cil­i­ty to pro­duce the drug.

Vedan­ta’s new 7,000-square-foot fa­cil­i­ties in Cam­bridge, MA, are de­signed to man­u­fac­ture clin­i­cal and com­mer­cial sup­plies for its port­fo­lio, in­clud­ing their oral c. dif­fi­cile can­di­date VE303.

The fa­cil­i­ty is an ex­ten­sion of the com­pa­ny’s ex­ist­ing man­u­fac­tur­ing ca­pa­bil­i­ties and can pro­duce mul­ti­ple drug can­di­dates, ac­cord­ing to Vedan­ta. It al­so has CGMP ca­pa­bil­i­ties to han­dle every­thing from clin­i­cal de­vel­op­ment to com­mer­cial launch. Man­u­fac­tur­ing is ex­pect­ed to kick off in Q4 of this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER